TY - JOUR
T1 - Most genetic risk for autism resides with common variation
AU - Gaugler, Trent
AU - Klei, Lambertus
AU - Sanders, Stephan J.
AU - Bodea, Corneliu A.
AU - Goldberg, Arthur P.
AU - Lee, Ann B.
AU - Mahajan, Milind
AU - Manaa, Dina
AU - Pawitan, Yudi
AU - Reichert, Jennifer
AU - Ripke, Stephan
AU - Sandin, Sven
AU - Sklar, Pamela
AU - Svantesson, Oscar
AU - Reichenberg, Abraham
AU - Hultman, Christina M.
AU - Devlin, Bernie
AU - Roeder, Kathryn
AU - Buxbaum, Joseph D.
N1 - Funding Information:
This study was supported by National Institute of Mental Health (NIMH) grants MH057881 and MH097849 and also in part through the computational resources and staff expertise provided by the Scientific Computing Facility at the Icahn School of Medicine at Mount Sinai. We thank the Mount Sinai Genomics Core Facility for carrying out Illumina bead array genotyping. We thank D. Cutler, M. Daly and S. Purcell for comments on the manuscript and M. Daly and P. Sullivan for facilitating access to control samples, collected and genotyped by M. Daly, C.M.H., P.S. and P. Sullivan with support from NIMH grants MH095034 and MH077139. We also thank the nurses, A.-K. Sundberg and A.-B. Holmgren, for their hard work in collecting the samples. AGP: We used data from the Autism Genome Project (AGP) Consortium Whole-Genome Association and Copy Number Variation Study of over 2,600 parent-offspring trios (database of Genotypes and Phenotypes (dbGaP) study phs000267.v4.p2). Funding for AGP was provided from the US NIH (HD055751, HD055782, HD055784, HD35465, MH52708, MH55284, MH57881, MH061009, MH06359, MH066673, MH080647, MH081754, MH66766, NS026630, NS042165 and NS049261); the Canadian Institutes for Health Research (CIHR); Assistance Publique–Hôpitaux de Paris, France; Autism Speaks, UK; the Canada Foundation for Innovation/Ontario Innovation Trust; grant Po 255/17-4 from Deutsche Forschungsgemeinschaft, Germany; the European Community’s Sixth Framework Programme AUTISM MOLGEN; Fundação Calouste Gulbenkian, Portugal; Fondation de France; Fondation FondaMental, France; Fondation Orange, France; Fondation pour la Recherche Médicale, France; Fundação para a Ciência e Tecnologia, Portugal; The Hospital for Sick Children Foundation and the University of Toronto, Canada; INSERM, France; Institut Pasteur, France; Convention 181 of 19.10.2001 from the Italian Ministry of Health; the John P. Hussman Foundation, USA; the McLaughlin Centre, Canada; Rubicon 825.06.031 from the Netherlands Organization for Scientific Research; TMF/DA/5801 from the Royal Netherlands Academy of Arts and Sciences; the Ontario Ministry of Research and Innovation, Canada; the Seaver Foundation, USA; the Swedish Science Council; the Centre for Applied Genomics, Canada; the Utah Autism Foundation, USA; and Core award 075491/Z/04 from the Wellcome Trust, UK. Genotype and phenotype data were obtained from dbGaP, as provided by AGP study investigators. HealthABC: These controls were obtained from dbGaP. Funding support for the CIDR Visceral Adiposity Study (dbGaP study phs000169.v1.p1) was provided through the Division of Aging Biology and the Division of Geriatrics and Clinical Gerontology, National Institute on Aging. The CIDR Visceral Adiposity Study includes a GWAS funded as part of the Division of Aging Biology and the Division of Geriatrics and Clinical Gerontology, National Institute on Aging. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by Health ABC study investigators. This manuscript reflects the views of the authors and does not necessarily reflect the opinions or views of the US NIH.
PY - 2014/8
Y1 - 2014/8
N2 - A key component of genetic architecture is the allelic spectrum influencing trait variability. For autism spectrum disorder (herein termed autism), the nature of the allelic spectrum is uncertain. Individual risk-associated genes have been identified from rare variation, especially de novo mutations 1-8. From this evidence, one might conclude that rare variation dominates the allelic spectrum in autism, yet recent studies show that common variation, individually of small effect, has substantial impact en masse 9,10. At issue is how much of an impact relative to rare variation this common variation has. Using a unique epidemiological sample from Sweden, new methods that distinguish total narrow-sense heritability from that due to common variation and synthesis of results from other studies, we reach several conclusions about autism's genetic architecture: its narrow-sense heritability is ∼52.4%, with most due to common variation, and rare de novo mutations contribute substantially to individual liability, yet their contribution to variance in liability, 2.6%, is modest compared to that for heritable variation.
AB - A key component of genetic architecture is the allelic spectrum influencing trait variability. For autism spectrum disorder (herein termed autism), the nature of the allelic spectrum is uncertain. Individual risk-associated genes have been identified from rare variation, especially de novo mutations 1-8. From this evidence, one might conclude that rare variation dominates the allelic spectrum in autism, yet recent studies show that common variation, individually of small effect, has substantial impact en masse 9,10. At issue is how much of an impact relative to rare variation this common variation has. Using a unique epidemiological sample from Sweden, new methods that distinguish total narrow-sense heritability from that due to common variation and synthesis of results from other studies, we reach several conclusions about autism's genetic architecture: its narrow-sense heritability is ∼52.4%, with most due to common variation, and rare de novo mutations contribute substantially to individual liability, yet their contribution to variance in liability, 2.6%, is modest compared to that for heritable variation.
UR - http://www.scopus.com/inward/record.url?scp=84905582433&partnerID=8YFLogxK
U2 - 10.1038/ng.3039
DO - 10.1038/ng.3039
M3 - Article
C2 - 25038753
AN - SCOPUS:84905582433
SN - 1061-4036
VL - 46
SP - 881
EP - 885
JO - Nature Genetics
JF - Nature Genetics
IS - 8
ER -